NY-CLINIQUE
2.2.2024 15:01:27 CET | Business Wire | Press release
Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center. The Center will develop forward-thinking research in dermatology, exploring the biological underpinnings of how skin ages, skin allergies and inflammatory or eczematous skin conditions, including eczema (or atopic dermatitis) and contact dermatitis. Rooted in a shared mission to conduct dermatological research that improves patients’ lives, the partnership will focus on applicable scientific discovery and leading-edge innovation to modernize allergy science in order to identify innovative solutions for these skin conditions.
Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims to uncover scientific findings to accelerate the creation of new topical and systemic treatments that help alleviate allergic skin conditions. The priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin. By investigating healthy skin, along with the skin of those with atopic dermatitis and other allergic skin disorders, the researchers may learn how to significantly slow the visible signs of aging in all people as well as in patients with eczema, who show signs of premature or accelerated aging. Insights from this research aim to spur advances in the field of dermatology and skin health. Additionally, they will inform and inspire Clinique in future product innovation to offer further solutions for people with allergic or sensitive skin.
“As a brand that has offered dermatologist guided solutions and allergy tested solutions since its inception, Clinique is proud to partner with the renowned institution of Icahn Mount Sinai and its team of physician-scientists, led by a world-renowned expert in allergic and inflammatory skin diseases, Dr. Emma Guttman. We are inspired by the team’s dedication to the research and future discoveries of allergic skin and its life impact, including aging. We are energized by our mutual commitment and steadfast belief that great skin can be created and maintained for all. I am confident that this first-of-its-kind partnership will enable groundbreaking research by leading physician-scientists dedicated to advancing allergy science,” Michelle Freyre, President, Global Brands, Clinique.
Dr. Emma Guttman, MD, PhD, Waldman Professor and System Chair, Department of Dermatology at the Icahn School of Medicine, a trailblazer in dermatologic science, has dedicated her career to bridging science with practice intended to improve patients’ lives. Her work has led to novel therapeutic targets for patients suffering from inflammatory skin conditions. Drawing inspiration from her personal and family history of eczema and other allergic conditions, Dr. Guttman has made it her mission to alleviate sensitive skin.
“Years of chronic inflamed skin plays a role in premature aging. Extensive research has helped us understand the molecular map of skin conditions associated with allergy such as eczema and contact dermatitis, and we’re now at a pivotal point in addressing these conditions and more. With Clinique’s support, we will continue to actively explore targeted approaches to reversing eczematous and allergic skin conditions with the goal of creating and sustaining healthy skin. In turn, we want to use this understanding to address and prevent the process of age-related inflammation or ‘inflammaging’ in the first place,” says Dr. Guttman, who also directs the Center of Excellence in Eczema at Mount Sinai and the Laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai.
The laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai has a major focus on atopic dermatitis, contact dermatitis, alopecia areata, and other inflammatory skin diseases. It has made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis, opening the door to new therapeutics. Dr. Guttman’s lab developed the only comprehensive molecular maps of atopic dermatitis, defining skin differentiation and immune-circuits characterizing this disease across phenotypes and ages. This work on atopic dermatitis/eczema has contributed directly to many of the recently developed treatments for this disease, earning Dr. Guttman and her lab a unique place as being a top leader in dermatology and immunology worldwide.
Clinique has a long-standing history of partnering with dermatologists, including its Founding Dermatologist, Norman Orentreich, MD, and incorporating patients’ insights in its innovation since 1968. His children, Catherine Orentreich, MD, and David Orentreich, MD, the brand’s Guiding Dermatologists, continue their father’s legacy for Clinique. Dr. David Orentreich is Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, and he and Dr. Catherine Orentreich are members of the Mount Sinai Dermatology Advisory Board.
In this meaningful mission, Clinique has made a philanthropic commitment of $5 million over seven years for the advancement and evolution of allergy science through the partnership and founding of the Mount Sinai-Clinique Healthy Skin Dermatology Center. The funds will be used to recruit the best and brightest physicians and scientists, and provide resources for the most advanced equipment, clinical and laboratory space, and key support staff. The studies conducted by the Mount Sinai-Clinique Healthy Skin Dermatology Center will include all ages, genders, races and ethnicities, and will also investigate the effects of factors such as diet, exercise, and stress on the skin of healthy people. Mount Sinai predicts that with Clinique’s support, critical breakthroughs will be fast-tracked, from the earliest stages of the multiyear partnership.
About Mount Sinai Health System:
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,400 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.
About Clinique:
In 1968, a beauty editor asked a leading New York City dermatologist, “Can great skin be created?” The answer: yes. And with that yes, Clinique was born. Today Clinique is the #1 Dermatologist Brand in Skincare in the US* and #1 Dermatologist Brand in Makeup in the US**, offering its dermatologist guided, allergy tested solutions for remarkable skin results. The brand is sold in 107 markets worldwide. Clinique’s clinical solutions are informed by years of research, working with dermatologists, scientists, and ophthalmologists. All Clinique formulas are designed to deliver powerful efficacy with rigorous safety —clinically proven, allergy tested, and 100% fragrance free.
*Source: Circana, U.S. Prestige Beauty Total Measured Market, Skincare Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023
**Source: Circana, U.S. Prestige Beauty Total Measured Market, Makeup Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023
Derm Brand is defined as a brand that was founded or developed by a dermatologist and/or is dermatologist recommended.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202954316/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify's Q2 Global Air Travel Fraud Report Finds Fraud Pressure Intensifying Across Middle East and Africa15.7.2026 13:00:00 CEST | Press release
Analysis of nearly 133 million airline booking transactions finds bookings departing from Cairo carried the world's highest fraud rate this quarter, while departure cities across the United States and Australia posted among the lowest fraud rates Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the release of its Global Air Travel Fraud Report: Q2 2026, a quarterly analysis examining how fraud pressure varies across global airline markets based on departure city at time of booking. Based on analysis of 132.9 million airline booking transactions processed between April and June 2026, the report evaluates prevented fraud rates across 537 departure cities that each processed at least 10,000 transactions during the quarter, providing airlines with a data-driven view of where Accertify's Predictive Yes platform intervened most frequently at booking. The Q2 findings rev
Forrester’s 2027 Budget Planning Guides: After A Year Of Caution, Business And Tech Leaders Are Ready To Invest Again15.7.2026 11:00:00 CEST | Press release
While leaders are betting on growth, in the age of AI, spending more is no longer enough According to Forrester’s (Nasdaq: FORR) 2027 Budget Planning Guides, business and technology leaders are approaching 2027 with renewed confidence as they increasingly accept volatility as a permanent feature of the business environment. After a year of more cautious spending, more than 80% of leaders expect their budgets to increase over the next 12 months, with as many as one-quarter anticipating growth of 10% or more. But planning in the age of AI demands more than bigger budgets: Increasing investment without modernizing operating models, strengthening data foundations, and improving AI readiness will only accelerate fragmented data, duplicated work, and technical debt. To realize AI’s full potential, leaders must rethink their strategies and prioritize investments in operational foundations, governance, and experimentation that drive tangible outcomes. This year, optimism is widespread across f
Post-Quantum’s Algorithm - Classic McEliece - Achieves Global ISO Standardization to Protect the World From Quantum Cyber Attack15.7.2026 10:00:00 CEST | Press release
Ultra-secure encryption algorithm added to ISO standard for Asymmetric Ciphers Classic McEliece is first PQC algorithm to achieve global standardization Organisations in 177 ISO member states can now adopt Classic McEliece to remain secure from attack by both classical and quantum computers Governments including Germany and the Netherlands already recommend the highly secure Classic McEliece algorithm due to its unmatched security credentials It’s proven that today’s encryption is vulnerable to attack by a sufficiently mature quantum computer running Shor’s algorithm - a catastrophic event commonly known as Q-Day. Even before such a cryptographically relevant quantum computer emerges it is known that adversaries are stealing encrypted data now, which can be decrypted later - also known as Harvest Now, Decrypt Later (HNDL). Google’s recent use of Artificial Intelligence (AI) to optimise Shor’s algorithm reduces the number of physical qubits required to break today’s encryption, therefor
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 09:00:00 CEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 09:00:00 CEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
